Loading...
XPARIVA
Market cap220mUSD
Dec 24, Last price  
2.24EUR
1D
-0.44%
1Q
19.15%
IPO
-73.65%
Name

Inventiva SA

Chart & Performance

D1W1MN
XPAR:IVA chart
P/E
—
P/S
9.17
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
17.16%
Rev. gr., 5y
48.60%
Revenues
23m
+90.19%
3,064,5143,282,9214,874,6669,445,6446,520,8163,197,0006,998,000372,0004,194,00012,179,00023,163,000
Net income
-110m
L+103.46%
-7,134,818-7,493,635-8,823,324-7,045,045-17,229,085-33,617,000-30,218,000-33,619,000-49,635,000-54,274,000-110,426,000
CFO
-82m
L+81.66%
-16,009,136-14,787,712-13,983,149-14,860,581-17,002,052-34,207,000-28,404,000-30,590,000-47,629,000-44,928,000-81,614,000
Earnings
Mar 26, 2025

Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
URL
https://inventivapharma.com/
IPO date
Feb 15, 2017
Employees
109
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
23,163
90.19%
12,179
190.39%
4,194
1,027.42%
Cost of revenue
132,322
76,959
60,989
Unusual Expense (Income)
NOPBT
(109,159)
(64,780)
(56,795)
NOPBT Margin
Operating Taxes
607
(20)
364
Tax Rate
NOPAT
(109,766)
(64,760)
(57,159)
Net income
(110,426)
103.46%
(54,274)
9.35%
(49,635)
47.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
28,079
8,827
25,475
BB yield
Debt
Debt current
5,308
5,851
1,282
Long-term debt
38,746
29,940
8,967
Deferred revenue
55
Other long-term liabilities
19,253
(1,000)
1,428
Net debt
15,641
(52,694)
(86,878)
Cash flow
Cash from operating activities
(81,614)
(44,928)
(47,629)
CAPEX
(540)
(561)
(534)
Cash from investing activities
(7,731)
8,868
(1,793)
Cash from financing activities
29,081
37,268
25,447
FCF
(111,507)
(68,948)
(52,897)
Balance
Cash
26,988
87,785
95,382
Long term investments
1,425
700
1,745
Excess cash
27,255
87,876
96,917
Stockholders' equity
(233,893)
(128,410)
(76,205)
Invested Capital
258,604
206,314
175,562
ROIC
ROCE
EV
Common stock shares outstanding
45,352
41,450
39,168
Price
Market cap
EV
EBITDA
(106,560)
(63,082)
(58,083)
EV/EBITDA
Interest
5,178
707
2,635
Interest/NOPBT